Drug Profile
Bemethyl - Algernon Pharmaceuticals
Alternative Names: NP 135Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Nash Pharmaceuticals
- Developer Algernon Pharmaceuticals; Nash Pharmaceuticals
- Class Antiepileptic drugs; Antifibrotics; Benzimidazoles; Nootropics; Small molecules; Sulfhydryl compounds
- Mechanism of Action Immunomodulators; Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Renal failure
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Renal-failure in Canada (PO)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in Canada (PO)
- 09 Sep 2019 Chemical structure information added;